SCHEMBL3018565

SCHEMBL3018565

Cc1cccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4F)CC3)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
USP2 O75604 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAPK1 P28482 3/20 0.45
SMN1; SMN2 Q16637 10/20 0.45
RAB9A P51151 6/20 0.45
NPC1 O15118 5/20 0.45
L3MBTL1 Q9Y468 4/20 0.44
ALDH1A1 P00352 3/20 0.44
LMNA P02545 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
FAAH O00519 1/20 0.42
TP53 P04637 2/20 0.42
THRB P10828 1/20 0.42
HTT P42858 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016173 0.92 MAPK1 (0.47) MAPTUSP2RECQLHSD17B10MAPK1
SCHEMBL3018127 0.91 CTSS (0.51) MAPTUSP2RECQLHSD17B10MAPK1
SCHEMBL3005459 0.91 MAPT (0.47) MAPTUSP2RECQLHSD17B10MAPK1
SCHEMBL3008483 0.90 SMN1; SMN2 (0.53) MAPTMAPK1SMN1; SMN2RAB9ANPC1
SCHEMBL3006459 0.89 SMN1; SMN2 (0.52) MAPTUSP2RECQLHSD17B10MAPK1
SCHEMBL3000176 0.89 MAPT (0.45) MAPTUSP2RECQLHSD17B10MAPK1
SCHEMBL3007137 0.88 MAPT (0.63) MAPTUSP2RECQLHSD17B10MAPK1
SCHEMBL3009720 0.88 MAPK1 (0.48) MAPTUSP2RECQLHSD17B10MAPK1
SCHEMBL3017062 0.88 MAPT (0.56) MAPTUSP2RECQLHSD17B10MAPK1
SCHEMBL3010416 0.87 SMN1; SMN2 (0.43) MAPTUSP2RECQLHSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885USP2 1831/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.